A development-stage company, Atossa Genetics owns and markets the MASCT (Mammary Aspirate Specimen Cytology Test) System, which was created by Atossa founder Steven Quay and tests for precursors to breast cancer. The MASCT System goes beyond mammograms in that it can detect genetic pre-cancerous conditions in the breast up to eight years before a mammography. Patented and approved by the FDA, the device is a handheld pump used to collect fluid from breast milk ducts in about 10 minutes. Atossa also offers related screening tests. The company filed an initial public offering (IPO) in 2010, but later withdrew the offering; it filed again in 2012.